CMS “Retail” Insurance Model: How Prescription Drugs Fit In
This article was originally published in RPM Report
The ACA exchange rules regarding formularies aren’t written the way most in the biopharma industry would like. But that is likely to change over time, assuming CMS’ vision of a “retail” health insurance market is correct.
You may also be interested in...
Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.